Thema: US02043Q1076
Alnylam Pharmaceuticals, US02043Q1076
stock-6690192_1920.jpg - Foto: THN
Alnylam Pharmaceuticals stock trades at 147.70 euros late Friday
Alnylam Pharmaceuticals stock was quoted late Friday. The company develops RNAi medicines for serious diseases.
ad-hoc-news.de, 30.10.26 21:00 Uhr
Alnylam Pharmaceuticals, US02043Q1076
UBS cuts target for Alnylam Pharmaceuticals stock from USD ...
Alnylam reports third-quarter results on October 29, 2026 after UBS kept Buy. Alnylam Pharmaceuticals stock costs EUR 203.70 on October 27, 2026.
ad-hoc-news.de, 27.10.26 21:45 Uhr
Alnylam Pharmaceuticals, US02043Q1076
Raymond James sets USD 420.00 target for Alnylam Pharmaceuticals ...
Alnylam reports results October 29, 2026. Alnylam Pharmaceuticals stock costs EUR 200.40 on October 23, 2026 versus Tradegate close.
ad-hoc-news.de, 24.10.26 20:55 Uhr
Alnylam Pharmaceuticals, US02043Q1076
Wells Fargo cuts Alnylam target to USD 253 for Alnylam Pharmaceuticals ...
Third-quarter results are due October 29, 2026. Alnylam Pharmaceuticals stock costs EUR 205.15 on October 20, 2026, 2.36 percent below Tradegate.
ad-hoc-news.de, 20.10.26 19:21 Uhr
Alnylam Pharmaceuticals, US02043Q1076
BofA cuts target to USD 336.00 for Alnylam Pharmaceuticals ...
Results are scheduled for October 29, 2026. Alnylam Pharmaceuticals stock closed at USD 231.83 on October 16, 2026, down 0.94 percent on Nasdaq.
ad-hoc-news.de, 17.10.26 20:55 Uhr
Alnylam Pharmaceuticals, US02043Q1076
Citigroup cuts target to USD 320 for Alnylam Pharmaceuticals ...
Second-quarter revenue reached USD 1.29 billion. Alnylam Pharmaceuticals stock costs EUR 207.45 on October 15, 2026, up 3.58 percent on Nasdaq.
ad-hoc-news.de, 15.10.26 21:41 Uhr
Alnylam Pharmaceuticals, US02043Q1076
Alnylam Pharmaceuticals stock gets a Strong Buy upgrade ...
Alnylam Pharmaceuticals stock received a Strong Buy upgrade from Zacks Research as of October 7, 2026. Q2 revenue rose 74 percent to USD 1.2 billion.
ad-hoc-news.de, 08.10.26 06:53 Uhr
Alnylam’s, Market
Alnylam’s Market Conundrum: Ambitious Targets Meet Investor ...
